IP Library Granted Patent US 8,148,431
Granted Patent B2
US 8,148,431 · App. 10/532,775 · Granted Apr 3, 2012

Osteogenesis promoter containing β-cryptoxanthin as the active ingredient

Assignee: Kemin Health, L.C.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,148,431
App. No.
10/532,775
Granted
Apr 3, 2012
Kind
B2
Abstract

It is intended to provide an osteogenesis promoter having a remarkable effect of positively promoting osteogenesis and thus preventing/treating bone diseases; a preventive/a remedy for bone diseases such as osteoporosis having both of an osteogenesis-promoting effect and a bone resorption-inhibiting effect; and a method of screening an active ingredient for preventing/treating bone diseases by using a compound having both of an osteogenesis-promoting effect and a bone resorption-inhibiting effect as a lead compound. It is confirmed that beta-cryptoxanthin, which occurs in a large amount in peel and sarcocarp of satsuma orange, has an osteogenesis-promoting effect and a therapeutic effect on bone disease. Thus, beta-cryptoxanthin or its composition is used as an osteogenesis promoter, a preventive/a remedy for bone diseases, a functional food or a food material for preventing/treating bone diseases and a feed composition.

Claims (9)

1. A method of ameliorating bone loss problems associated with aging in a person in need thereof, comprising administering to the person in need thereof an amount of purified β-cryptoxanthin effective to ameliorate the bone loss problems associated with aging.

2. A method as defined in claim 1 , wherein the amount is between about 100 and about 1000 μg per kilogram of body weight.

3. A method as defined in claim 1 , wherein the amount is between about 0.5 mg and about 10 mg.

4. A method of ameliorating osteoporosis in a person in need thereof, comprising administering to the person in need thereof an amount of purified β-cryptoxanthin effective to ameliorate the osteoporosis.

5. A method as defined in claim 4 , wherein the amount is between about 100 and about 1000 μg per kilogram of body weight.

6. A method as defined in claim 4 , wherein the amount is between about 0.5 mg and about 10 mg.

7. A method of promoting osteogenesis in a person in need thereof, comprising administering to the person in need thereof an amount of purified β-cryptoxanthin effective to promote osteogenesis.

8. A method as defined in claim 7 , wherein the amount is between about 100 and about 1000 μg per kilogram of body weight.

9. A method as defined in claim 7 , wherein the amount is between about 0.5 mg and about 10 mg.

Assignments (3)
RELEASE OF SECURITY INTEREST Recorded Jul 6, 2026
From: BANK OF AMERICA, N.A., AS COLLATERAL AGENT
To: KEMIN FOODS, L.C.; KEMIN HOLDINGS, L.C.; KEMIN INDUSTRIES, INC.
Reel/Frame 075184/0539 →
IP SUPPLEMENT (PATENTS) Recorded Apr 15, 2016
From: KEMIN FOODS, L.C.; KEMIN INDUSTRIES, INC.; KEMIN HOLDINGS, L.C.
To: BANK OF AMERICA, N.A., AS COLLATERAL AGENT
Reel/Frame 038439/0522 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 16, 2005
From: YAMAGUCHI, MASAYOSHI
To: KEMIN FOODS, L.C.
Reel/Frame 016644/0732 →
Priority Claims (1)
JP 2002-311930 · Oct 25, 2002 · national
Continuity (1)
Related Publication 20060106115A1 · May 18, 2006